Skip to main content
SpringerLink
Log in

Hormontherapie

  • Chapter
Koronare Herzkrankheit bei Frauen

  • 41 Accesses

Zusammenfassung

Vor der Menopause ist das Auftreten einer KHK immer noch die Ausnahme. Nach der Menopause (dem Zeitpunkt der Reduktion der ovariellen Hormonproduktion) steigt die Prävalenz der KHK jedoch mit zunehmdendem Alter kontinuierlich an und erreicht bei Frauen über 75 Jahre das Niveau gleichaltriger Männer. Das Risiko der KHK ist bei jungen Frauen <35 Jahren) mit vorzeitiger oder chirurgisch induzierter Menopause und fehlender Hormonsubstitution um das Doppelte erhöht (Wenger et al. 1993). Diese Fakten haben zu der Annahme geführt, dass endogene Östrogene kardioprotektiv wirken und somit hauptverantwortlich für die geringe prämenopausale Prävalenz der KHK bei der Frau sind. In der Tat ist aber die Rolle der endogenen Hormone fü Pathogenese der KHK unklar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861–1867

    Article  PubMed  CAS  Google Scholar 

  • Bergkvist L, Adami HO, Persson I et al. (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy. AM J Epidemiol 130:221–228

    PubMed  CAS  Google Scholar 

  • Blumenthal RS, Zacur HA, Reis SE, Post WS (2000) Beyond the null hypo thesis - Do the HERS results disprove the estrogen/coronary heart disease hypothesis? Am J Cardiol 85:1015–1017

    Article  PubMed  CAS  Google Scholar 

  • Brett KM, Madans JH (1995) Long-term survival after coronary heart disease: comparisons between men and women in anational sampie. Ann Epidemiol 5:25–32

    Article  PubMed  CAS  Google Scholar 

  • Bush TL (1991) Long-term effect of estrogen use on cardiovascular death in women. AHA Meeting, November 1991, Oriando/FL

    Google Scholar 

  • Bush TL, Barrett-Connor E, Cowan LO et al. (1987) Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics Program follow-up study. Circulation 75:1102–1109

    Article  PubMed  CAS  Google Scholar 

  • Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589

    Article  PubMed  CAS  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidermiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059

    Article  Google Scholar 

  • Collins P, Rosana G, Sarrel PM et al. (1995) Estrogen attenuates acetylcholineinduced coronary arterial constriction in women but not in men with coronary heart disease. Circulation 92:24–30

    Article  PubMed  CAS  Google Scholar 

  • Criqui MH, Suwarez L, Barrett-Connor E et al. (1988) Postmenopausal estrogen use and mortality. Am J Epidemiol 128:606–614

    PubMed  CAS  Google Scholar 

  • Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on the risk of breast cancer in post-menopausal women: Results from the MORE (Multiple Outcomes ofRaloxifene Evaluation) trial. JAMA 281:2189

    Article  PubMed  CAS  Google Scholar 

  • Cushman M, Legault C, Barrett-Connor E et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal estrogen/progestin interventions (PEPI) study.Circulation 100:717

    Article  PubMed  CAS  Google Scholar 

  • Daly E, Vessey MP, Hawkins MM et al. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977

    Article  PubMed  CAS  Google Scholar 

  • Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72

    Article  PubMed  CAS  Google Scholar 

  • Fleming KC (1999) Hormone replacement therapy: practical prescribing. In: Charney P (ed) Coronary artery disease in women. American College of Physicians, Philadelphia, p 294

    Google Scholar 

  • Folsom AR, Mink PT, Seilers TA et al. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Publ Health 85:1128–1132

    Article  CAS  Google Scholar 

  • Gerhard M, Ganz M (1995) How do we explain the clinical benefits of estrogen? Circulation 92:5

    Article  PubMed  CAS  Google Scholar 

  • Gilligan DM, Quyyumi AA, Connon RO III (1994) Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2541–2551

    Article  Google Scholar 

  • Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women.Ann Intern Med 117:1016–1037

    PubMed  CAS  Google Scholar 

  • Grady G, Gebretsadik T, Kerlikowske K et al. (1995) Hormone replacement therapy and endometrial cancer risk; A meta-analysis. Obstet Gynecol 85:304–313

    Article  PubMed  CAS  Google Scholar 

  • Grady D, Hulley SB, Furberg C (1997) Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477

    Article  PubMed  CAS  Google Scholar 

  • Grady D, Wenger NK, Herrington D et al. (2000) Postmenopausal hormone therapy increases risk for venous thrombembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 132:689–696

    PubMed  CAS  Google Scholar 

  • Grodstein F, Stampfer MJ, Goldhaber SZ et al. (1996a) Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983

    Article  PubMed  CAS  Google Scholar 

  • Grodstein F, Stampfer MJ, Manson JE et al. (1996b) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 332:1589

    Google Scholar 

  • Grodstein F, Stampfer MJ, Colditz GA et al. (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769

    Article  PubMed  CAS  Google Scholar 

  • Grodstein F, Manson JE, Stampfer MJ et al. (1999) Postmenopausal hormones and recurrence of coronary events in the Nurses’ Health Study (abstract). Circulation 100: 1–871

    Article  Google Scholar 

  • Henderson BE, Paganini-Hill A, Ross RK. (1988) Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159:312–317

    PubMed  CAS  Google Scholar 

  • Henderson BE, Paganini-Hill A, Ross RK (1999) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78

    Article  Google Scholar 

  • Herrington DM (1999) The HERS trial results: Paradigms lost? Ann Intern Med 131:463

    PubMed  CAS  Google Scholar 

  • Herrington DM, Beboussin KB, Brosnihan KB et al. (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522–529

    Article  PubMed  CAS  Google Scholar 

  • Herrington DM (2001) What about estrogens now? Curr J Rev 10(2)

    Google Scholar 

  • Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  • Jick H, Derby LE, Myers MW et al. (1996) Risk of hospital admission for idiopathie venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981

    Article  PubMed  CAS  Google Scholar 

  • Khovidhunkit W, Shoback DM (1999) Clinieal effects of raloxifene hydrochloride in women. Ann Intern Med 130:431

    PubMed  CAS  Google Scholar 

  • Lobo RA: Hormones, hormone replacement therapy, and heart disease. In Douglas PS (ed): Cardiovascular Health and Disease in Women. WB Saunders, Philadelphia, 1993, p 153

    Google Scholar 

  • Love RR, Newcomb PA, Wiebe DA et al. (1990) Effects of tamoxifene therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82:1327

    Article  PubMed  CAS  Google Scholar 

  • Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801

    Article  PubMed  CAS  Google Scholar 

  • Miller BA, Ries LAG, Hankey BF et al. (eds) (1992) Cancer Statisties Review: 1973-89. National Cancer Institute, Washington DC, NIH pub no 92, p 2789

    Google Scholar 

  • Nachtigall LE, Nachtigall RH, Nachtigall RD et al. (1979) Estrogen replacement therapy. Part II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74–79

    Article  PubMed  CAS  Google Scholar 

  • Nachtigall M, Smilen SW, Nachtigall RD et al. (1992) Incidence ofbreast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80:827–830

    PubMed  CAS  Google Scholar 

  • Newton KM (1995) Estrogen replacement therapy and prognosis after first myocardial infarction [Abstract]. AHA Meeting, November 1995, San Diego/CA

    Google Scholar 

  • Pamela S, Douglas PS (2001) Coronary artery disease in women. In: Braunwald E, Zipes DP, Libby P (eds) Heart disease. Saunders, Philadelphia

    Google Scholar 

  • Reis SE, Gloth ST, Blumenthai RS et al. (1994) Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89:52–60

    Article  PubMed  CAS  Google Scholar 

  • Rieh-Edwards JW, Manson JE, Hennekens CH et al. (1995) The primary prevention of coronary heart disease in women. N Engl J Med 332:1758–1766

    Article  Google Scholar 

  • Ridker PM, Hennekens CN, Rifai N et al. (1999) Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713

    Article  PubMed  CAS  Google Scholar 

  • Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifene: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398

    Article  PubMed  CAS  Google Scholar 

  • Sack MN, Rader DJ, Cannon RO III (1994) Oestrogen and inhibition of oxidation oflow-density lipoproteins in postmenopausal women. Lancet 343:269–270

    Article  PubMed  CAS  Google Scholar 

  • Stampfer MJ, Willett WC, Colditz GA et al. (1986) A prospective study of postmenopausal estrogen therapy, and coronary heart disease. N Engl J Med 313:1044–1049

    Article  Google Scholar 

  • Stampfer MJ, Colditz GA, Willett WC et al. (1991) Postmenopausal es trogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health study. N Engl J Med 325:756

    Article  PubMed  CAS  Google Scholar 

  • Steinberg KK, Thacker SB, Smith JC (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk ofbreast cancer. JAMA 265:1985–1990

    Article  PubMed  CAS  Google Scholar 

  • Sullivan JM, Vander Zwaag R, Hughes JP et al. (1990) Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 150:2557–2562

    Article  PubMed  CAS  Google Scholar 

  • Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KK (1995) Estrogen replacement therapy after coronary artery bypass surgery: Effect on survival. Circulation 345:669

    Google Scholar 

  • The American-Canadian Cooperative Study Group (1986) Persantine Aspirin Trial in cerebral ischemia. Part III:Risk factors for stroke. Stroke 17:12–18

    Article  Google Scholar 

  • The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogenl progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199–208

    Article  Google Scholar 

  • Walsh BW, Kuller LH, Wild RA et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445

    Article  PubMed  CAS  Google Scholar 

  • Weiner CP, Lizasoain I, Baylis SA et al. (1994) Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91:5212–5216

    Article  PubMed  CAS  Google Scholar 

  • Wenger NK, Speroff L, Packard B (1993) Cardiovascular health and disease in women. N Engl J Med 329:247–526

    Article  PubMed  CAS  Google Scholar 

  • Williams JK, Adams MR, Herrington DM, Clarkson TB (1992) Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 20:452–457

    Article  PubMed  CAS  Google Scholar 

  • Wilson PWF, Garrison RJ, Castelli WP (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over so: the Framingham Study. N Engl J Med 313:1038–1043

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wishard Health Services, Krannert Institute of Cardiology, 1800 N. Senate Blvd., Indianapolis, IN, USA, 46202

    Dr. Elisabeth von der Lohe (Associate Professor of Cardiology, Chief of Cardiology)

Authors
  1. Dr. Elisabeth von der Lohe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von der Lohe, E. (2002). Hormontherapie. In: Koronare Herzkrankheit bei Frauen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56041-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56041-5_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42051-4

  • Online ISBN: 978-3-642-56041-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation